The hits just keep on coming: All eyes on naproxen

Hot on the heels of the announcement that Celebrex can increase risk of cardiovascular adverse events discovered during a clinical trial to see if Celebrex might assist in preventing colorectal cancer, NIH has announced that naproxen sodium (trade name Aleve) has been shown in a three-year trial to increase the chance of CV events over placebo. (The latter clinical trial was the ADAPT, or Alzheimer's Disease Anti-Inflammatory Prevention Trial.)

CNN is reporting that those who took naproxen were 50 percent more likely to experience CV events than those who took a placebo, but both NIH and FDA are relatively quiet on percents thus far.